Phaseline

Targets › CLK3

CLK3 (Dual specificity protein kinase CLK3): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Apr 2027.

Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex. (UniProt, P49761)

Open in Phaseline: the race on CLK3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Asociación Europea y Latinoamericana SELNET para la Investigación en SarcomasCirtuvivint (SM08502)
CLK1-4 and DYRK1-4 kinase inhibitor
CLK1, CLK2, CLK3, CLK4, DYRK1Phase 2Soft Tissue Sarcoma (STS)Apr 2027
Washington University School of MedicineCirtuvivint
CDC2-like kinase (CLK) and dual-specificity tyrosine-regulated kinase (DYRK) inhibitor
CLK1, CLK2, CLK3, CLK4Phase 1Small-cell Lung CancerJul 2028
University of Colorado, DenverCirtuvivint
Pan CDC-like kinase (CLK) and dual specificity tyrosine kinase (DYRK) inhibitor with Wnt i
CLK1, CLK2, CLK3, CLK4Phase 1Endometrioid Ovarian CancerDec 2029

Conditions

Small-cell Lung Cancer (1) Endometrioid Ovarian Cancer (1) Soft Tissue Sarcoma (STS) (1)

Modalities

small molecule (3)

Companies

Washington University School of Medicine (1) University of Colorado, Denver (1) Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas (1)

Related targets

CLK1 (3) CLK2 (3) CLK4 (3) DYRK1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.